Prognosis and treatment outcomes in anti-GBM (Goodpasture) disease
Official title: Prognosis of Anti-GBM Antibody Disease Through an International Cohort
Run by Region Skane · NCT07018024 · Data updated 2026-11-12
The study will see how different treatments and early blood or urine markers at diagnosis relate to outcomes for people with anti-GBM (Goodpasture) disease.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | Region Skane Academic / other |
| Locations | 1 site (Lund) |
| Status | Recruiting |
| Started | January 1, 2024 |
| Main results expected | December 2028 |
| Study ends | December 2028 |
| Registry record updated | June 25, 2025 |
| Trial ID | NCT07018024 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are people diagnosed with anti-GBM disease who either (A) were diagnosed on or after January 1, 2010 with available initial treatment records from participating centers able to include >80% of their patients, or (B) have a blood or urine sample from the time of diagnosis and known survival status at six months.
✕Probably not a fit
People without available initial treatment records or without diagnostic blood/urine samples and six‑month survival information are unlikely to be included and thus may not benefit from this study's findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational project collects clinical records and diagnostic blood or urine samples to clarify prognosis in the rare anti-GBM condition. It has two overlapping arms: Arm A includes patients diagnosed from January 1, 2010 onward with available information about initial treatment and comes from centers with a search strategy that captures >80% of their patients. Arm B includes patients from any time period who have stored blood and/or urine samples from diagnosis and known six‑month survival status. Data from a single patient can be included in both arms to link treatment, biomarkers, and short‑term outcomes.
Why it matters
Potential benefit: If successful, the study could help clinicians predict outcomes and tailor treatment decisions using early biomarkers and real‑world treatment experience.
How similar studies have gone: Previous observational registries have provided some prognostic information in anti‑GBM disease, but biomarker‑guided outcome prediction is still limited and relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Arm A: Inclusion Criteria: * Anti-GBM disease diagnosed 01-01-2010 - 31-12-2027 * Available information about initial treatment Arm B: Inclusion Criteria: * Anti-GBM disease diagnosis (no time limit) * Available blood and/or urine sample at the time of diagnosis * Available information about patient survival at six months
Where it's running
-
Lund
Lund, Sweden Recruiting
Study contacts
- Study coordinator: Mårten Segelmark, MD, PhD, Professor
- Email: marten.segelmark@med.lu.se
- Phone: +46702871990
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.